The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
General Updates | How to optimally sequence agents in the expanding treatment armamentarium of multiple myeloma
Ezzat El Hassadi, MD, University Hospital Waterford, Waterford, Ireland, outlines the challenges associated with treatment sequencing in multiple myeloma, commenting on the remarkable efficacy of CAR-Ts in this setting, and highlighting the possibility to incorporate CAR-T therapy earlier in the treatment algorithm of multiple myeloma. This interview was recorded virtually.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
